

November 11, 2021

**The BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E), Mumbai – 400 051

**Scrip Code: 541540**

**Scrip Code: SOLARA**

Dear Sirs,

**Sub:** Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended from time to time

This is in continuation to our letters dated 9th April 2021 and 25th August 2021 intimating the approval of the Board of Directors of the Company to the Composite Scheme of Amalgamation (Merger by Absorption) and Arrangement (the "Scheme") under Sections 230 to 232 and Section 66 of the Companies Act, 2013 read with other applicable provisions and the Rules framed thereunder ("the Act") of Aurore Life Sciences Private Limited ("Aurore Life Sciences" or the "Amalgamating Company 1" or "Transferor Company 1") and Empyrean Lifesciences Private Limited ("Empyrean" or the "Amalgamating Company 2" or "Transferor Company 2") and Hydra Active Pharma Sciences Private Limited ("Hydra" or the "Amalgamating Company 3" or "Transferor Company 3") with Solara Active Pharma Sciences Limited ("Solara" or "Transferee Company" or "Company") and their respective shareholders whereby Hydra, Empyrean and Aurore Life Sciences, along with its investment in Aurore Pharmaceuticals Private Limited ("APPL") were getting merged with Solara.

This Scheme has been filed with BSE Limited ("BSE") and National Stock Exchange Limited ("NSE") and is currently pending for approval before them.

In view of the outstanding issue with the minority shareholder of APPL (Subsidiary of Aurore Life Sciences), the Board, in its meeting held today, has considered and approved the withdrawal of the Scheme. Further, the Board has approved the Revised Scheme (wherein APPL will not be transferred to Solara) and accordingly a separate intimation of the same has been made to the BSE and NSE.

The same may kindly be read in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to take the same on record.

Thanking you,  
Yours faithfully,

**For Solara Active Pharma Sciences Limited**



**S. Murali Krishna**  
Company Secretary